EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Oncology QCARD Initiative: Fostering efficient evaluation of initial real‐world data proposals

Donna R Rivera iD, Joy C Eckert, Carla Rodriguez-Watson, Catherine C Lerro, Monica M Bertagnolli, Rebecca A Hubbard, Lawrence H Kushi, Jennifer L Lund iD, Deborah Schrag, Shirley V Wang iD, William A Wood, Jennifer J Lee und 4 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Donna R Rivera und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Research Design, Medical Oncology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The oncology quality, characterization, and assessment of real‐world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real‐world data (RWD) source(s) proposed in an initial study concept as part of early interaction with scientific reviewers.

Methods

A multidisciplinary executive committee (EC) was established to guide the Oncology QCARD Initiative. The EC conducted a landscape review of published literature, guidances, and guidelines to evaluate relevant dimensions of data quality measurement. Guided by the review and informed by expert feedback, the Oncology QCARD Initial Protocol Characterization (IPC) provides a summary of minimum elements needed to adequately describe an initial clinical study concept that involves RWD and is intended to support decision‐making.

Results

Fit‐for‐use data and fit‐for‐purpose design emerged as themes from the landscape analysis. Data that are fit‐for‐use are both relevant (sufficiently capturing exposure, outcomes, and covariates) and reliable (understanding data accrual and quality control and whether the data represent the underlying concepts they are intended to represent) to answer a specific research question. A fit‐for‐purpose design takes appropriate steps to ensure internal and external validity and allows for transparency in reporting. The QCARD‐IPC focuses on high‐level characteristics of RWD sources and study design domains including data temporality, population, medical product exposure, comparators, and covariates, endpoints, statistical analysis, and data quality assurance plans.

Conclusions

Evaluation of studies including RWD requires understanding the data source, study design, and potential biases to preliminarily evaluate whether selected RWD are fit‐for‐use for the research question. The Oncology QCARD‐IPC provides a structured, transparent approach to facilitate early review and enhanced communication between study sponsors and scientific reviewers of initial study proposals including RWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignMedical OncologyHumansData AccuracyNeoplasms

Stichwörter der Autor:innen

data qualityfit‐for‐purposeobservational study designoncologyreal‐world datareal‐world evidence

Autor:innen und Institutionen

  • Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC, USA.
  • Alliance for Clinical Trials in Oncology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Donna R Rivera, Jennifer L Lund, Shirley V Wang, Paul G Kluetz

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Rivera, D. R., Eckert, J. C., Rodriguez-Watson, C., Lerro, C. C., Bertagnolli, M. M., Hubbard, R. A., Kushi, L. H., Lund, J. L., Schrag, D., Wang, S. V., Wood, W. A., Lee, J. J., Okafor, C., Ghauri, K., Winckler, S. C., & Kluetz, P. G. (2024). The Oncology QCARD Initiative: Fostering efficient evaluation of initial real‐world data proposals. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5818

Vancouver

Rivera DR, Eckert JC, Rodriguez-Watson C, Lerro CC, Bertagnolli MM, Hubbard RA, et al. The Oncology QCARD Initiative: Fostering efficient evaluation of initial real‐world data proposals. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5818

BibTeX
@article{Rivera2024,
  author = {Rivera, Donna R and Eckert, Joy C and Rodriguez-Watson, Carla and Lerro, Catherine C and Bertagnolli, Monica M and Hubbard, Rebecca A and Kushi, Lawrence H and Lund, Jennifer L and Schrag, Deborah and Wang, Shirley V and Wood, William A and Lee, Jennifer J and Okafor, Cristeen and Ghauri, Kanwal and Winckler, Susan C and Kluetz, Paul G},
  title = {The Oncology QCARD Initiative: Fostering efficient evaluation of initial real‐world data proposals},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5818}
}
Kostenlos starten →